Introduction
============

Bladder cancer (BC), the most frequently occurring urogenital malignancy of the urinary tract worldwide, results in substantial morbidity and mortality ([@b1-ol-0-0-9002],[@b2-ol-0-0-9002]). In the USA, bladder cancer is the fourth most common cancer, with 76,960 estimated new cases and 16,390 mortalities in 2016 ([@b3-ol-0-0-9002]). In addition to other carcinoma types, such as cervical ([@b4-ol-0-0-9002]), prostate ([@b5-ol-0-0-9002]) and ovarian cancer ([@b6-ol-0-0-9002]), the accumulation of inherited and somatic mutations in oncogenes and tumor suppressor genes are believed to be the reason for the occurrence, progression and metastasis of BC ([@b7-ol-0-0-9002]--[@b9-ol-0-0-9002]). Although a number of cancer-associated genes and cellular pathways have been proven to be associated with the initiation and development of BC ([@b10-ol-0-0-9002],[@b11-ol-0-0-9002]), the accuracy of early diagnosis, therapeutic and prognostic evaluation for BC remains low. Consequently, investigating the molecular mechanisms, including the proliferation, apoptosis and invasion of BC is crucial for the progress of diagnostic and treatment strategies. With the development of gene microarray technology, various advanced techniques for assessing gene expression have been widely applied in assessing tumor development and progression with lower expenses, compared with past decades ([@b12-ol-0-0-9002],[@b13-ol-0-0-9002]). In previous years, numerous gene expression profiling studies on BC have revealed hundreds of differentially expressed genes (DEGs) and provided substantial functional information on gene regulatory network analysis ([@b14-ol-0-0-9002]--[@b16-ol-0-0-9002]). However, comparative analysis of DEGs reported by independent research appears to rarely display substantial overlap ([@b17-ol-0-0-9002]), and no reliable biomarker profile discriminating cancerous from non-cancerous samples has been identified. At present, due to bioinformatics methods, the data generated by microarray technology have been analyzed in order to identify mRNA expression changes in collected urothelial cells and to examine DEGs in BC and non-cancerous urothelial cells ([@b18-ol-0-0-9002]). However, the interactions among DEGs, particularly pathways in the interaction network, remain to be elucidated.

In the present study, original data (data set GSE31189) were downloaded from the Gene Expression Omnibus (GEO) ([@b19-ol-0-0-9002]), in order to identify DEGs between BC and non-cancerous urothelial cells. Then, functional annotation and network analyses were performed to identify DEGs. By analyzing the biological functions and networks of BC, the present study may be useful to gain a better understanding of BC development at a molecular level and explore the potential candidate biomarkers for diagnosis, prognosis and treatment.

Materials and methods
=====================

### Data source

The GSE31189 gene expression profile and its corresponding platform annotation files were downloaded from the GEO database. This data set was submitted by Professor Virginia Urquidi on 3rd August 2011, last updated on 21st April 2017 and stockpiled on the GPL570 platform (HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA). This gene expression data consisted of the data of 92 samples, including 52 BC and 40 non-cancerous urothelial cells.

### Data preprocessing and screening of DEGs

The probes without annotation of the gene expression profiles were filtered using the Affy package ([@b20-ol-0-0-9002]), which is based on the Bioconductor principles of reproducibility, transparency and efficiency of development ([@b21-ol-0-0-9002]). The probe ID for each gene was then transformed into a gene symbol using the Affymetrix Human Genome U133 Plus 2.0 Array annotation data (hgu133plus2.db) and Genome wide annotation for Human, version: 3.7 (org. Hs.eg.db) packages from Bioconductor (<http://www.bioconductor.org/>). For a gene symbol corresponding to multiple probe IDs, the average value of these probes was calculated as the representative expression level of this gene. The DEGs were screened by using the Linear Models for Microarray Analysis package in R software (R ×64 3.3.3) ([@b22-ol-0-0-9002]) with cut-off criteria of P\<0.05 and \|log~2~ fold-change (FC)\|\>0.5.

### Functional annotation and pathway enrichment

Gene Ontology analysis (GO) is a common useful approach for annotating genes and gene products and for identifying characteristic biological phenomena for high-throughput genome or transcriptome data ([@b23-ol-0-0-9002],[@b24-ol-0-0-9002]). To describe gene product attributes, GO provides three categories of defined terms, including biological process (BP), cellular component (CC) and molecular function (MF) categories ([@b25-ol-0-0-9002]). Kyoto Encyclopedia of Genes and Genomes (KEGG) is an integrated database resource for the systematic analysis of gene functions, linking genomic information with higher-order functional information ([@b26-ol-0-0-9002]). The two analyses were available in the Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>; date of access, 8/02/2018), which is a bioinformatics data resource composed of an integrated biology knowledge base and analysis tools to extract biological meanings from large quantities of genes and protein collections through a novel agglomeration algorithm ([@b27-ol-0-0-9002]). In the present study, GO term analysis and KEGG pathway analysis were performed using the DAVID online tool. P\<0.05 was set as the cut-off criterion.

### PPI network construction and analysis of modules

Search Tool for the Retrieval of Interacting Genes (STRING) database (<http://string-db.org/>) is an online software designed to assess protein-protein interaction (PPI) information, including direct (physical) and indirect (functional) associations ([@b28-ol-0-0-9002]). In the present study, the DEGs were mapped using STRING to evaluate the PPI information with a combined score of \>0.4 set as the cut-off criterion. Then, the PPI network was visualized using Cytoscape 3.5.0 ([@b29-ol-0-0-9002]). To screen the hub genes, a node degree of ≥10 was selected as the threshold. Furthermore, the Molecular Complex Detection (MCODE) plug-in was used to screen modules of hub genes from the PPI network with degree threshold=10, haircut on, node score cut-off=0.2, k-core=2 and maximum depth=100 ([@b30-ol-0-0-9002]). The genes in the significant modules were further mapped to GO terms and KEGG pathways for functional analysis.

### PrognoScan database analysis

The overall survival (OS) rate of mRNA expression was assessed using an online database, PrognoScan (<http://www.abren.net/PrognoScan/>; keywords: NOD2, S100A9, CXCL1, CXCR2; date of access, 8/02/2018), which is a platform used for evaluating potential tumor markers and therapeutic targets. To evaluate the OS rate of patients with breast cancer, patient samples were divided into two groups by median expression \[high vs. low expression; Threshold: NOD (0.87), S100A9 (0.77), CXCL1 (0.68), CXCR2 (0.55)\] and analyzed using PrognoScan, with a hazard ratio with 95% confidence intervals and Cox\'s Proportional-Hazards Model.

Results
=======

### Data processing and DEG screening

With a criteria of the false discovery ratio \<0.05 and \|log~2~ FC\|≥0.571, a total of 976 DEGs (when compared with those of the noncancerous urothelial cells) were identified in the BC samples, including 457 upregulated genes and 519 downregulated genes ([Fig. 1](#f1-ol-0-0-9002){ref-type="fig"}).

### Functional enrichment of DEGs

DAVID analysis was performed to predict the potential functions and mechanisms of BC by mapping the upregulated and downregulated genes using GO terms and the KEGG pathways. The top five significant GO terms of the BP, CC and MF categories enriched by the up- and downregulated DEGs were identified ([Figs. 2](#f2-ol-0-0-9002){ref-type="fig"} and [3](#f3-ol-0-0-9002){ref-type="fig"}). The results demonstrated that the upregulated genes were mainly involved in the negative regulation of the apoptotic process in the BP category, constituted integral components of the plasma membrane in the CC category, and were mainly involved in protein binding in the MF category ([Fig. 2](#f2-ol-0-0-9002){ref-type="fig"}), whereas the downregulated genes were mainly associated with cell proliferation in the BP category, were mainly intracellular in the CC category, and were mainly involved in metal ion binding in the MF category ([Fig. 3](#f3-ol-0-0-9002){ref-type="fig"}). The results for the KEGG pathway enrichment are shown in [Fig. 4](#f4-ol-0-0-9002){ref-type="fig"}, which indicated that the upregulated genes were significantly enriched in amoebiasis, malaria, osteoclast differentiation, Legionellosis, Chagas disease, advanced glycation end product-receptor for AGE signaling pathway in diabetic complications, salmonella infection, toxoplasmosis, tumor necrosis factor (TNF) signaling pathway and rheumatoid arthritis pathways, while the downregulated genes were mainly enriched in cell adhesion molecules, oxidative phosphorylation, taurine and hypotaurine metabolism, collecting duct acid secretion, vitamin digestion and absorption, rheumatoid arthritis and vibrio cholerae infection pathways.

### Construction of a PPI network and functional analysis for key genes

The Cytoscape tool visually constructed the PPI network with 98 nodes and 321 edges, which were predicted using STRING with a PPI score of \>0.4 ([Fig. 5](#f5-ol-0-0-9002){ref-type="fig"}). In the PPI network, 28 nodes with a degree of ≥10 were regarded as key genes ([Table I](#tI-ol-0-0-9002){ref-type="table"}), including interleukin (IL)-1B, matrix metalloproteinase (MMP)9, heat shock protein family A (Hsp70) member 6, FGR proto-oncogene, Src family tyrosine kinase, ribosomal protein S6 kinase A1, TNF receptor superfamily member 1A, RAS-like family 11 member B, MMP1, chemokine ligand (CCL)5, C-X-C motif chemokine receptor 2 (CXCR2), C-X-C motif chemokine ligand 1 (CXCL1), Pim-1 proto-oncogene, serine/threonine kinase, nucleotide binding oligomerization domain containing 2 (NOD2), CCL20, src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites, serine threonine kinase 21B, S100 calcium binding protein A9 (S100A9), Kruppel-like factor 8, phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 β, cluster of differentiation 83, renin, G protein subunit α 15, transporter 1, ATP binding cassette subfamily B member, secretory leukocyte peptidase inhibitor, NME/NM23 family member 5, BCS homolog, ubiquinol-cytochome c reductase complex chaperone, cell division cycle 20 and NME/NM23 nucleoside diphosphate kinase 3. One module including 12 nodes and 62 edges was obtained using MCODE ([Fig. 6](#f6-ol-0-0-9002){ref-type="fig"}). The heat map indicated that the 12 genes were able to distinguish the two groups of cell samples, in that their expression was distinctly different between the two groups ([Fig. 7](#f7-ol-0-0-9002){ref-type="fig"}). GO term enrichment analysis demonstrated that in the BP category, the genes in this module were significantly involved in the chemokine-mediated signaling pathway, fever generation, inflammatory responses, immune responses and the positive regulation of cell division ([Table II](#tII-ol-0-0-9002){ref-type="table"}). The genes were significantly enriched in the CC category were significantly part of the extracellular space, autophagosome, cytoplasmic vesicle, extracellular matrix and lysosome ([Table II](#tII-ol-0-0-9002){ref-type="table"}). Finally, in the MF category, analysis revealed that the genes were mainly associated with chemokine activity, IL-1 receptor binding, C-C motif receptor chemokine receptor, cytokine activity and metalloendopeptidase activity ([Table II](#tII-ol-0-0-9002){ref-type="table"}). KEGG analysis revealed that the genes were mainly enriched in the TNF signaling pathway, rheumatoid arthritis, prion diseases, cytokine-cytokine receptor interaction and NOD-like receptor signaling pathway ([Table II](#tII-ol-0-0-9002){ref-type="table"}).

### Association between 12 key genes and prognosis in patients with BC

The PrognoScan database was used to perform the association analysis of mRNA expression and OS rate in patients with BC. As presented in [Table III](#tIII-ol-0-0-9002){ref-type="table"} and [Fig. 8](#f8-ol-0-0-9002){ref-type="fig"}, the high expression of NOD2 (P\<0.05), S100A9 (P\<0.001), CXCL1 (P\<0.05) and CXCR2 (P\<0.01) were significantly associated with a poor prognosis in patients with BC.

Discussion
==========

BC is the ninth most common genitourinary malignancy, globally and resulted in 165,000 mortalities in 2012 ([@b31-ol-0-0-9002]--[@b33-ol-0-0-9002]). Understanding the molecular mechanism of BC is of great importance for diagnosis and treatment. Due to well-developed microarray and high-throughput sequencing technology, it is now easier to determine the general genetic alterations in the progression of diseases, and has been widely adopted to predict potential diagnosis and therapeutic targets for BC ([@b34-ol-0-0-9002]).

In the present study, data were extracted from the GSE31189 dataset and 457 upregulated and 519 downregulated DEGs between BC and normal control specimens were identified using bioinformatics analysis. The upregulated genes were enriched in the negative regulation of apoptotic processes and the positive regulation of cell division, while the downregulated genes were mainly involved in cell proliferation, bicellular tight junction, mitochondrial matrix and immune responses. Furthermore, by constructing the PPI, a number of key genes were identified that may be useful in future therapeutic studies on BC. Notably, key nodes in the PPI network and genes in the significant modules, including *NOD2, S100A9, CXCL1* and *CXCR2*, may have specific contributions to the occurrence and development of BC.

The *NOD2* gene, a member of the evolutionarily conserved Nod-like receptors family, is located on chromosome 16q21 ([@b35-ol-0-0-9002],[@b36-ol-0-0-9002]). Wang *et al* revealed that the abnormal expression of NOD2 was highly expressed in primary liver tumor types, which was associated with a shorter median survival time ([@b36-ol-0-0-9002]). In addition, in the present study, a higher NOD2 mRNA expression was identified in BC, which was associated with a shorter OS rate.

S100A9, a member of the S100 family of calcium-binding proteins, is primarily detected in neutrophil granulocytes and known to serve a function in the innate immune system ([@b37-ol-0-0-9002],[@b38-ol-0-0-9002]). Previous studies have demonstrated that the abnormal overexpression of S100A9 is an unfavorable prognostic factor for carcinogenesis and prognosis in various neoplasms, such as hypopharyngeal and bladder cancer ([@b39-ol-0-0-9002]--[@b43-ol-0-0-9002]). Additionally, S100A9 is associated with colorectal carcinoma progression and contributes to colorectal carcinoma cell survival and migration via the Wnt/β-catenin pathway ([@b37-ol-0-0-9002]). In the present study, S100A9 was revealed to be differentially expressed in BC and non-cancerous urothelial cells and was identified as a key node in the PPI network constructed using DEGs between these two groups. The results additionally demonstrated that a high *S100A9* expression was associated with a shorter OS rate. Therefore, this gene may be an essential marker for the diagnosis and prognosis of BC.

CXCL1, a member of the CXC chemokine family, was originally characterized by Wang *et al* ([@b44-ol-0-0-9002]) and is known to promote the proliferation of melanoma cells. Previous studies have demonstrated that CXCL1 may be associated with tumor epithelial-stromal interactions that facilitate tumor growth and invasion ([@b45-ol-0-0-9002]--[@b47-ol-0-0-9002]). In addition, Wang *et al* ([@b48-ol-0-0-9002]) revealed that CXCL1 derived from tumor-associated lymphatic endothelial cells drives gastric cancer cells into the lymphatic system by activating integrin β1/focal adhesion kinase/protein kinase B (Akt) signaling. Furthermore, Kawanishi *et al* ([@b49-ol-0-0-9002]) revealed that CXCL1 may modulate the invasive abilities of BC cells, and therefore is a potential candidate biomarker and therapeutic target for invasive BC. In the present study, a higher CXCL1 mRNA expression was identified in patients with BC in the GSE31189 gene expression profile. Furthermore, PrognoScan analysis results revealed that high CXCL1 expression was significantly associated with a shorter OS rate. Due to these findings, the expression level of CXCL1 may be a useful prognostic marker of BC.

CXCR2, the co-receptor of IL-8 and CXCL1, is an important therapeutic target in a number of solid tumor types, including lung, breast, prostate, ovarian, colorectal and liver cancer ([@b50-ol-0-0-9002]--[@b55-ol-0-0-9002]). Xu *et al* ([@b56-ol-0-0-9002]) revealed that CXCR2 may promote breast cancer metastasis and chemoresistance via the suppression of AKT serine/threonine kinase 1 and activation of cyclooxygenase 2. Inhibition of CXCR2 may reduce the activity of breast cancer stem cells and improve the survival of human epidermal growth factor receptor 2 (HER2)-positive patients in combination with HER2-target chemotherapies ([@b57-ol-0-0-9002]). Furthermore, Gao *et al* ([@b58-ol-0-0-9002]) demonstrated that the CXCL5/CXCR2 axis may promote BC cell migration and invasion by activating the phosphoinositide 3-kinase/Akt-induced upregulation of MMP2/MMP9. In the present study, CXCR2 was increased in BC compared with normal specimens, similar with the previous studies. However, the BC patients with higher mRNA levels of CXCR2 were predicted to have a better OS rate. As few studies have focused on CXCR2, the underlying function of CXCR2 requires further research.

Altogether, the DEGs identified in the BC urothelial cells when compared with the normal controls may be involved in tumorigenesis. The key nodes identified in the PPI network constructed with these DEGs and genes involved in the significant module, including *NOD2, S100A9* and *CXCL1*, may be important in the development of BC, and may provide valuable clues in order to investigate the pathogenesis of BC. However, further biological experimental evidence is required in order to confirm the function of the identified gene in BC.
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![DEG analysis of the GSE31189 data set. DEGs were identified using the Linear Models for Microarray Analysis package. Blue indicates downregulated genes, red indicates upregulated genes and black indicates genes with unchanged expression. DEG, differentially expressed gene; FC, fold-change; down, downregulated; no, no change; up, upregulated.](ol-16-03-3092-g00){#f1-ol-0-0-9002}

![GO analysis of upregulated genes of the GSE31189 data set. GO, Gene Ontology; MF, molecular function; CC, cellular component; BP, biological process.](ol-16-03-3092-g01){#f2-ol-0-0-9002}

![GO analysis of downregulated genes of the GSE31189 data set. GO, Gene Ontology; MF, molecular function; CC, cellular component; BP, biological process.](ol-16-03-3092-g02){#f3-ol-0-0-9002}

![KEGG pathway enrichment analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cellular component; TNF, tumor necrosis factor; AGE-RAGE, advanced glycation end product-receptor for AGE.](ol-16-03-3092-g03){#f4-ol-0-0-9002}

![Protein-protein interaction network of differentially expressed genes. Red nodes denote upregulated genes, green nodes denote downregulated genes.](ol-16-03-3092-g04){#f5-ol-0-0-9002}

![One significant module selected from the protein-protein interaction network. Red nodes denote upregulated genes, green nodes denote downregulated genes.](ol-16-03-3092-g05){#f6-ol-0-0-9002}

![Hub genes expression heat map in the GSE31189 data set. Red indicates upregulation and green indicates downregulation.](ol-16-03-3092-g06){#f7-ol-0-0-9002}

![Association between mRNA expression and overall survival rate in patients with bladder cancer (using the PrognoScan database). P\<0.05 was used as the threshold. NOD2, nucleotide binding oligomerization domain containing 2; S100A9, S100 calcium binding protein A9; CXCL1, C-X-C motif chemokine ligand 1; CXCR2, C-X-C motif chemokine receptor 2; HR, hazard ratio.](ol-16-03-3092-g07){#f8-ol-0-0-9002}

###### 

Key nodes in the protein-protein interaction network with a degree ≥10.

  Gene       Degree of change   Log~2~ fold-change
  ---------- ------------------ --------------------
  IL-1B      23                 1.211413
  MMP9       22                 0.762970
  HSPA6      20                 1.198230
  FGR        18                 0.674802
  RPS6KA1    18                 −0.692775
  TNFRSF1A   17                 0.601014
  RASL11B    16                 −0.600296
  MMP1       15                 0.743885
  CCL5       15                 −0.698948
  CXCR2      15                 0.988178
  CXCL1      15                 1.088843
  PIM1       14                 0.686538
  NOD2       14                 0.633431
  CCL20      14                 0.677125
  SRMS       13                 −0.619940
  STK21B     13                 −0.598366
  S100A9     13                 1.202516
  KLF8       13                 −0.585851
  PIK3c2B    12                 −0.604130
  CD83       12                 0.801585
  REN        12                 −0.737372
  GNA15      12                 0.647069
  TAP1       11                 1.004478
  SLPI       11                 1.064963
  NME5       11                 −0.905805
  BCS1L      10                 −0.621588
  CDC20      10                 0.646275
  NME3       10                 −0.709424

###### 

Functional and pathway enrichment analysis of the genes in the module.

  Category       Term                                                                          Count   \%     P-value
  -------------- ----------------------------------------------------------------------------- ------- ------ --------------
  GO BP          GO:0070098-chemokine-mediated signaling pathway                               3       40.4   1.09×10^−04^
  GO_BP          GO:0001660-fever generation                                                   2       27.0   2.00×10^−03^
  GO_BP          GO:0006954-inflammatory response                                              3       40.4   3.14×10^−03^
  GO_BP          GO:0006955-immune response                                                    3       40.4   3.21×10^−03^
  GO_BP          GO:0051781-positive regulation of cell division                               2       27.0   5.48×10^−03^
  GO_CC          GO:0005615-extracellular space                                                5       47.4   1.86×10^−04^
  GO_CC          GO:0005776-autophagosome                                                      2       27.0   1.67×10^−02^
  GO_CC          GO:0031410-cytoplasmic vesicle                                                2       27.0   3.19×10^−02^
  GO_CC          GO:0031012-extracellular matrix                                               2       27.0   3.66×10^−02^
  GO_CC          GO:0005764-lysosome                                                           2       27.0   4.73×10^−02^
  GO_MF          GO:0008009-chemokine activity                                                 3       40.4   1.16×10^−04^
  GO_MF          GO:0005149-interleukin-1 receptor binding                                     2       27.0   4.78×10^−03^
  GO_MF          GO:0048020-C-C motif receptor chemokine receptor binding                      2       27.0   1.01×10^−02^
  GO_MF          GO:0005125-cytokine activity                                                  2       27.0   4.28×10^−02^
  GO_MF          GO:0004222-metalloendopeptidase activity                                      2       27.0   4.95×10^−02^
  KEGG_PATHWAY   ecb04668: Tumor necrosis factor signaling pathway                             6       80.9   4.39×10^−09^
  KEGG_PATHWAY   ecb05323: Rheumatoid arthritis                                                5       67.4   3.04×10^−07^
  KEGG_PATHWAY   ecb05020: Prion diseases                                                      3       40.4   3.42×10^−04^
  KEGG_PATHWAY   ecb04060: Cytokine-cytokine receptor interaction                              4       53.9   5.48×10^−04^
  KEGG_PATHWAY   ecb04621: Nucleotide oligomerization domain-like receptor signaling pathway   3       40.4   8.04×10^−04^

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes. The count was the number of enriched genes in each term. If there were \>5 terms enriched in this category, the top five terms were selected according to their P-value.

###### 

Association between mRNA expression of enriched genes and overall survival in patients with bladder cancer.

  Gene name   End point               PROBE ID       n     Cox P-value   Hazard ratio
  ----------- ----------------------- -------------- ----- ------------- --------------
  CCL5        Overall survival rate   ILMN_1773352   165   0.112459      1.2
  SLPI        Overall survival rate   ILMN_1669650   165   0.225693      1.09
  S100A9      Overall survival rate   ILMN_1714991   165   0.000119      1.28
  CXCL1       Overall survival rate   ILMN_1787897   165   0.013803      1.23
  TNFRSF1A    Overall survival rate   ILMN_1685005   165   0.732444      1.08
  CCL20       Overall survival rate   ILMN_1657234   165   0.636372      0.95
  MMP1        Overall survival rate   ILMN_1726448   165   0.279756      1.07
  NOD2        Overall survival rate   ILMN_1762594   165   0.025039      1.45
  IL1B        Overall survival rate   ILMN_1775501   165   0.374688      1.10
  CXCR2       Overall survival rate   ILMN_1783085   165   0.006080      0.59
  CD83        Overall survival rate   ILMN_1780582   165   0.169956      1.27
  MMP1        Overall survival rate   ILMN_1796316   165   0.114052      1.15
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